---
title: "Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Indication questions"
description: "Indication questions on Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Ibrance approved for with an aromatase inhibitor or fulvestrant? When was Ibrance first approved? 2 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Indication questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)

Indication questions that apply to every indication of Ibrance are on [Ibrance (palbociclib), all indications: Indication](https://www.evicenter.com/medical-information/ibrance/indication).

## Indication

<a id="ibrance-indication"></a>

### What is Ibrance approved for with an aromatase inhibitor or fulvestrant?

> “IBRANCE<sup>®</sup> (palbociclib) 125 mg capsules and tablets are indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
> an aromatase inhibitor as initial endocrine-based therapy; or
> fulvestrant in patients with disease progression following endocrine therapy.”

Source: [IBRANCE: HR+/HER2- mBC | IBRANCE® (palbociclib) | Safety Info, captured 2026-11-13](https://ibrance.pfizerpro.com/af#:~:text=%28palbociclib%29%20125%20mg%20capsules%20and,disease%20progression%20following%20endocrine%20therapy.)

Note: The IBRANCE label also lists use with inavolisib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative disease, and a HER2-positive maintenance indication; this page covers the aromatase inhibitor and fulvestrant combinations.

<a id="ibrance-first-approval"></a>

### When was Ibrance first approved?

> “Initial U.S. Approval: 2015”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Initial%20U.S.%20Approval%3A%202015)

> “IBRANCE was initially approved in combination with letrozole for the treatment of postmenopausal women with ER+/HER2- advanced breast cancer as initial endocrine-based therapy for their metastatic disease.”

Source: [IBRANCE: About IBRANCE® (palbociclib) for HCPs, captured 2026-11-13](https://ibrance.pfizerpro.com/about/ibrance-experience#:~:text=IBRANCE%20was%20initially%20approved%20in,therapy%20for%20their%20metastatic%20disease.)

## Related pages
- [Medical information: Ibrance (palbociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Clinical trials](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
